Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

BERLIN & BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer AG announced today the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer's Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies (CGT) entrepreneurs with access to Bayer's enterprise wide expertise in addition to state-of-the-art laboratory and office space. “The opening of our Co.Lab Cambridge in the same location as the Bayer.

Bayer Opens First Co.Lab Life Science Incubator in Cambridge

Bayer stock is a textbook example of investing in a wonderful company at a fair price with an estimated upside potential between 30% - 120%. The group is suffering from a conglomerate discount and investors are basically getting the Bayer pharma business almost for free.

Bayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'

WHIPPANY, N.J.--(BUSINESS WIRE)--Today the Consumer Health North America division of Bayer announced a new strategic collaboration with two of New Jersey's leading polytechnic universities – New Jersey Institute of Technology (NJIT) and Stevens Institute of Technology (Stevens). Bayer is partnering with these universities to create unique learning opportunities for students in the field of data science as a way to educate, engage and inspire the next generation of data science talent in NJ. A g.

Bayer Announces New Strategic Collaboration with New Jersey's Leading Polytechnic Universities to Cultivate Data Science Talent in Region

Ambev

Anheuser-Busch InBev

Experian PLC

Novozymes A/S

Roche Holding AG

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The April 2023 Heat Map

Bill Anderson said he needs time to get to know the German owner of Monsanto before offering any remedies for the its woes.

Bayer's New American CEO Treads Softly as He Takes On Wounded Pharma Giant

Deutsche Bank

With 2-5 year U.S. Treasury securities currently yielding 3-4%, it makes great sense to search for equities that offer us both a competitive dividend with possible upside potential. Add to that diversifying one's portfolio with top-rated equities in the world's fourth-largest economy.

Searching For Potential German Portfolio Winners

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer further expands the global clinical development program for NUBEQA® (darolutamide) in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of NUBEQA plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

The one-of-a-kind B2B platform, developed in partnership with Microsoft, offers a cloud-based infrastructure and ready-to-use digital capabilities for Agri-food Industry. BANGALORE, India , March 15, 2023 /PRNewswire/ -- Sonata Software, a leading Modernization and Digital Engineering company, has announced that it has been chosen as one of the TOP SI partners of the newly launched cloud solution developed by Bayer for the agri-food industry.

Sonata Software chosen as a TOP SI partner for Bayer's new Agri-food Cloud solution

SAN FRANCISCO--(BUSINESS WIRE)--Following a 2021 strategic partnership announcement with Microsoft, Bayer today launched new cloud-based solutions for the agri-food industry: AgPowered Services from Bayer in combination with the new Microsoft Azure Data Manager for Agriculture provide ready-to-use capabilities available for businesses and organizations from start-ups to global enterprises to license and use for their own internal or customer-facing digital solutions.

Bayer collaborates with Microsoft to unveil new cloud-based enterprise solutions, advancing innovation and transparency in the agri-food industry

WHIPPANY, N.J.--(BUSINESS WIRE)--More than two billion people lack access to safe water around the world. This includes in the U.S., which has its share of regionalized water-related issues. A new study from The Harris Poll, commissioned by Bayer, confirms Americans recognize the myriad concerns associated with water, including inequitable access, safety and combatting drought.

Bayer US Joins the Fight to Combat Water Crisis

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, World Kidney Day, results from a survey designed to gain a broader understanding of the attitudes and challenges faced by healthcare professionals (HCPs) in diagnosing, managing and treating people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) were announced. The survey was executed by Bayer and fielded in partnership with MedSurvey, a leading medical market research company.

World Kidney Day: A Bayer Survey Reveals Physicians Agree on Need for Earlier Testing and Increased Transparent Communication for People Diagnosed With Chronic Kidney Disease Associated With Type 2 Diabetes

Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters.

Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head

ST. LOUIS--(BUSINESS WIRE)--Bayer is changing the future of agriculture by introducing the Preceon™ Smart Corn System, marking a new era in corn production. The system will help farmers protect their crop and optimize decision-making throughout the season for sustained success.

Bayer Unveils the Preceon™ Smart Corn System, Transforming How Farmers Manage Their Corn Crop

Reckitt Benckiser Group PLC

Sanofi

Tencent Holdings Limited

International Wide-Moat Stocks On Sale - The March 2023 Heat Map

Apple

AbbVie

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season.

My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales

Bayer reported great results for fiscal 2022 with sales growing in the double digits, core EPS growing 22% and all three segments contributing to growth. And although Bayer is a little cautious for fiscal 2023 and expecting EBITDA and core EPS to decline, we can be optimistic about its long-term growth potential.

Bayer: Improving Business And Still Undervalued

Bayer delivered strong FY 2022 results, beating analyst consensus estimates with regards to both topline and earnings. However, markets punished the stock lower following the earnings release, due to a perceived weak 2023 outlook.

Bayer: Disappointing Outlook Doesn't Change The Deep Value Thesis

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

Bayer AG (OTCPK:BAYZF) Q4 2022 Results Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Oliver Maier - Head of Investor Relations Werner Baumann - Chairman, Chief Executive Officer and Chief Sustainability Officer Rodrigo Santos - President, Crop Science Division Stefan Oelrich - Head, Pharmaceuticals Division Heiko Schipper - President, Consumer Health Division Wolfgang Nickl - Chief Financial Officer Conference Call Participants Michael Leuchten - UBS James Quigley - Morgan Stanley Richard Vosser - J.P. Morgan Keyur Parekh - Goldman Sachs Peter Verdult - Citigroup Laurent Favre - Exane BNP Paribas Sachin Jain - Bank of America Merrill Lynch Christian Faitz - Kepler Cheuvreux Vincent Andrews - Morgan Stanley Operator Good day and thank you for standing by.

Bayer AG (BAYZF) Q4 2022 Earnings Call Transcript

Bayer (ETR: BAYN) share price plunged to the lowest level since February 6 after the company lowered its forward guidance. It retreated to a low of €55.95, which was about 15% below the highest level this year.

Bayer share price has nosedived: is it a good turnaround stock?

Bayer AG shares BAYN, -4.66% fell on Tuesday after the company said fourth-quarter net profit fell, noting that it had a higher number of lawsuits related to its allegedly harmful weedkiller Roundup in 2022 than in 2021.

Bayer shares slide on lower fourth-quarter net profit; weedkiller claims rose in 2022

Bayer AG on Tuesday reported net profit for the fourth quarter of 2022 that missed consensus expectations despite higher sales, and said it expects earnings for 2023 to be lower than the prior year as inflation remains high.

Bayer warns on 2023 earnings as inflation remains high, after disappointing quarter

Agriculture and pharmaceuticals company Bayer said operating earnings would likely decline in 2023, hurt by higher costs and by the reversal of last year's price boost for its glyphosate-based weedkillers.

Bayer sees lower 2023 operating profit on cost inflation

BASEL, Switzerland & MONHEIM, Germany--(BUSINESS WIRE)--As a part of the company's vision “Health for all, Hunger for None,” Bayer announces the expansion of one of its signature sustainability programs, the Nutrient Gap Initiative, to now improve access to both nutritious food and safety net supplementation.

Bayer Expands its “Nutrient Gap Initiative” to Help End Malnutrition

Bayer AG is a $50-billion multinational life sciences conglomerate based in Germany. The company is trading at a discount of at least 20% compared to its peers as well as to its historical multiples.

Bayer AG: Potential To Double Over 12-18 Months

News for Bayer AG Stock (BAYRY)